Read this Science Advisory Board article by Samantha Black, Ph.D., about GlaxoSmithKline’s presentation at BioProcess International Digital Week.
SAB-Article_Bioprocessing_R1
Access the original article.
Find out how the Opto™ CLD workflow lets you generate the best production cell lines for complex antibody therapeutics with >99% monoclonality assurance in just days.
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.
See how the Opto CLD 2.0 Workflow enables rapid generation of cell lines secreting antibodies for both traditional and non-traditional antibodies while acquiring a superior data package.